AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2%
Fri, 5 Jun

AUROBINDO PHARMA has announced its results for the quarter ended March 2020. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-19*
3
Dec-19*
3
Mar-20*
QoQ ChangeYoY Change
Net SalesRs m52,92257,99461,5846.2%16.4%
Other incomeRs m3233093265.4%1.0%
TurnoverRs m53,24558,30461,9106.2%16.3%
ExpensesRs m42,34746,87048,4223.3%14.3%
Gross profitRs m10,21511,95113,28511.2%30.1%
DepreciationRs m1,8662,5012,324-7.1%24.5%
InterestRs m501371318-14.2%-36.4%
Profit before taxRs m8,1709,38810,96816.8%34.2%
TaxRs m2,3112,3292,285-1.9%-1.1%
Profit after taxRs m5,8597,0608,68323.0%48.2%
Gross profit margin%19.320.621.6
Effective tax rate%28.324.820.8
Net profit margin%11.012.114.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 16.4% on a year-on-year (YoY) basis. The expenses were up by 14.3% YoY during the same period.
  • The company's operating profit increased by 30.1% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 21.6% in 4QFY20 as against 19.3% in 4QFY19.
  • Depreciation charges increased by 24.5% and finance costs declined by 36.4% YoY, respectively.
  • Other income increased by 1.0% YoY during the quarter.
  • Net profit for the quarter increased by 48.2% YoY. Net profit margins during the quarter increased from 11.0% in 4QFY19 to 14.0% in 4QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 6.2% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.3% QoQ during the same period.
  • The company's operating profit increased by 11.2% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 21.6% in 4QFY20 as against 20.6% in 3QFY19.
  • Net profit for the quarter increased by 23.0% QoQ, while net profit margins increased from 12.1% in 3QFY19 to 14.0% in 4QFY20.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

Access Now: Eight Steps to Your Eight Figure Fortune

AUROBINDO PHARMA Share Price Performance

Over the last one year,AUROBINDO PHARMA share price has moved up from Rs 654.1 to Rs 765.3, registering a Gain of Rs 111.2 or around 17.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 16,273.6 (up 1.1%). Over the last one year it has moved up from 13,292.6 to 16,273.6, a gain of 2,981 points (up 22.4%).

Overall, the S&P BSE SENSEX is down 14.4% over the year.

Current Valuations

At the current price of Rs 765.3, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 15.7 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.2 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 24, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS